In Phase C, participants will get ABBV-744 and oral navitoclax. In Segment D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until finally sickness progression or the participants are unable to tolerate the study drugs. Celastrol was recognized like a Myb inhibitor that suppressed C/EBPβ activity and repressed https://eldero099gtd3.mywikiparty.com/user